Predictors of Sinonasal Improvement After Highly Effective Modulator Therapy in Adults with Cystic Fibrosis

Authors

Daniel M. Beswick, University of California, Los Angeles
Christine M. Liu, University of California, Los Angeles
Jonathan B. Overdevest, Columbia University
Anna Zemke, University of Pittsburgh
Aastha Khatiwada, National Jewish Health
David A. Gudis, Columbia University
Jessa E. Miller, University of California, Los Angeles
Adam Kimple, University of North Carolina at Chapel Hill
Jeremy P. Tervo, Columbia University
Emily DiMango, Columbia University
Jennifer L. Goralski, University of North Carolina, Chapel Hill
Claire Keating, Columbia University
Brent Senior, University of North Carolina at Chapel Hill
Amanda L. Stapleton, University of Pittsburgh
Patricia H. Eshaghian, University of California, Los Angeles
Jess C. Mace, Oregon Health & Science University
Karolin Markarian, University of California, Los Angeles
Jeremiah A. Alt, University of Utah
Todd E. Bodner, Portland State UniversityFollow
Naweed I. Chowdhury, Vanderbilt Health, Nashville
Anne E. Getz, University of Colorado
Peter H. Hwang, Stanford University
Ashoke Khanwalker, University of Colorado
Jivianne T. Lee, University of California, Los Angeles
Douglas A. Li, University of California, Los Angeles
Meghan Norris, University of North Carolina at Chapel Hill
Jayakar V. Nayak, Stanford University
Cameran Owens, University of Colorado
Zara M. Patel, Stanford University
Katie Poch, National Jewish Health
Rodney J. Schlosser, Medical University of South Carolina
Kristine A. Smith, University of Utah
Timothy L. Smith, Oregon Health & Science University

Published In

The Laryngoscope

Document Type

Article

Publication Date

4-18-2024

Subjects

Cystic fibrosis, Cystic fibrosis -- Pathophysiology

Abstract

The 22-question SinoNasal Outcome Test (SNOT-22) assesses chronic rhinosinusitis (CRS) severity. We aimed to identify predictors of SNOT-22 score improvement following highly effective modulator therapy (HEMT) initiation and to corroborate the SNOT-22 minimal clinically important difference (MCID) in adults with cystic fibrosis (CF).

Rights

Copyright (c) 2024 The Authors

This work is licensed under a Creative Commons Attribution 4.0 International License.

Locate the Document

https://doi.org/10.1002/lary.31438

DOI

10.1002/lary.31438

Persistent Identifier

https://archives.pdx.edu/ds/psu/41826

Citation Details

Beswick, D. M., Liu, C. M., Overdevest, J. B., Zemke, A., Khatiwada, A., Gudis, D. A., Miller, J. E., Kimple, A., Tervo, J. P., DiMango, E., Goralski, J. L., Keating, C., Senior, B., Stapleton, A. L., Eshaghian, P. H., Mace, J. C., Markarian, K., Alt, J. A., Bodner, T. E., … Taylor Cousar, J. L. (2024). Predictors of Sinonasal Improvement After Highly Effective Modulator Therapy in Adults with Cystic Fibrosis. The Laryngoscope. Portico.